SUPPLEMENTARY MATERIAL

SUPPLEMENTARY METHODS
Phase III Clinical Trial Simulations
The model describing OKZ exposure-response relationship was used to perform clinical trial simulations with DAS28(CRP) as the efficacy endpoint. 500 trials of 350 subjects per dose (placebo, 40, 60, 100, 120, 160, 200, 240, 300, 320, 400 and 480 mg) given Q2W or Q4W were simulated. Parameters were generated using simpar functionality within the MIfuns version 5.1 R-package, developed by Metrum Institute (http://metruminstitute.org). All simulations were performed in NONMEM.
SUPPLEMENTARY RESULTS
Immunogenicity Investigations
Despite the use of a study specific cut-off based on blinded analysis of all available baseline samples from the study, 13 subjects in OKZ groups, 5 subjects in the placebo groups and 2 subjects in the TCZ group were anti-OKZ antibody positive. Importantly, pre-dose samples for 4 of these 13 subjects in OKZ groups were also anti-OKZ Ab positive, suggesting a high level of false positives amongst these nominally anti-drug antibody positive samples.
In order to test the hypothesis of interference by non-specific immunoglobulins, anti-OKZ antibody positive samples from several subjects were pre-incubated with excess OKZ, isotype-matched control, different isotype control (IgG1), iv immune globulin (IVIG), or with infliximab. As expected, the anti-OKZ signal was reduced by excess OKZ, due to absorption of the anti-OKZ antibodies.
However, a reduction of the signal was also observed in most of the samples pre-incubated with non-OKZ immunoglobulins, suggesting that not all of the anti-OKZ antibodies measured by the immunogenicity assay are specific to OKZ. Therefore, the true incidence of specific anti-OKZ antibodies were likely less than reported, due to inherent sensitivity issues within the assay.
In addition, graphical analysis of the PK profile of all the nominative anti-OKZ antibody positive subjects indicated that only 1 subject (120 mg Q4W group) fit the profile of true immunogenicity impact, including trough concentrations well below expectations, no signs of drug accumulation and steep drug plasma concentration declines. Incubation of samples from this patient with each of the aforementioned immunoglobulins revealed that only OKZ immunoglobulins could reduce the immunogenicity signal, indicating an OKZ-specific response and confirming the anti-OKZ antibody positive status of the patient.
Immunogenicity and efficacy evaluations
Of the 13 nominally anti-OKZ antibody positive patients from the OKZ treatment groups patients, 6 received OKZ Q2W and 7 received OKZ Q4W, from a total of 5 treatment arms. These patients included those who had received doses of 60 mg, 120 mg and 240 mg OKZ. Thus no effect of treatment dose or frequency was observed (Table S1 ).
These 13 patients also exhibited varied clinical efficacy (Table S1 ). One patient achieved an ACR70 response at Week 12, one achieved an ACR50 response and 4 achieved an ACR20 response. Change from baseline in DAS28(CRP) and DAS28(ESR) ranged from -3.84-0.85 and -4.00-0.35, respectively. Diamonds represent the mean of 500 simulations, each of 350 patients; dashed bar represents median; box indicates 25% and 75% quantiles. Whiskers extend to distances computed as 75% quantile+1.5*(interquantile range) and 25% quantile-1.5*(interquantile range).
